Thrombosis Research
Volume 126, Issue 3 , Pages 232-237 , September 2010

Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry

  • Christoph Robier

      Affiliations

    • Central Laboratory, Department of Internal Medicine, Hospital Barmherzige Brueder Graz-Eggenberg, Austria
    • Corresponding Author InformationCorresponding author. Central Laboratory, Hospital Barmherzige Brueder, Graz-Eggenberg, Bergstrasse 27, A-8020 Graz, Austria. Tel.: +43 316 5989 6671; fax: +43 316 5989 1505.
    • ,
  • Manfred Neubauer

      Affiliations

    • Central Laboratory, Department of Internal Medicine, Hospital Barmherzige Brueder Graz-Eggenberg, Austria
    • ,
  • Heinz Sternad

      Affiliations

    • Central Laboratory, Department of Internal Medicine, Hospital Barmherzige Brueder Graz-Eggenberg, Austria
    • ,
  • Franz Quehenberger

      Affiliations

    • Institute of Medical Informatics, Statistics and Documentation, Medical University of Graz, Austria
    • ,
  • Franz Rainer

      Affiliations

    • Central Laboratory, Department of Internal Medicine, Hospital Barmherzige Brueder Graz-Eggenberg, Austria
    • ,
  • Peter Neumeister

      Affiliations

    • Department of Hematology, Medical University of Graz, Austria

Received 2 February 2010 ,Revised 7 June 2010 ,Accepted 17 June 2010.

References 

  1. Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol. 2002;29:16–21
  2. Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in the myeloproliferative disorders. Thromb Haemost. 1997;78:617–621
  3. Michiels J, Berneman Z, Schroyens W, Vliet HV. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets. 2004;15:67–84
  4. Elliott M, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2004;128:275–290
  5. Wehmeier A, Südhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost. 1997;23:391–402
  6. Cortelazzo S, Marchetti M, Orlando E, Falanga A, Barbui T, Buchanan M. Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: Role of the lipoxygenase pathway. Am J Hematol. 1998;57:277–282
  7. Landolfi R, Gennaro LD, Novarese L, Patrono C. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: Current insights and rationale for future studies. Semin Thromb Hemost. 2006;32:251–259
  8. Cacciola R, Francesco ED, Pezzella F, Tibullo D, Giustolisi R, Cacciola E. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. Acta Haematol. 2007;118:215–218
  9. Harrison C, Campbell P, Buck G, Wheatley K, East C, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45
  10. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–2232
  11. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005;353:85–86
  12. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007;109:5104–5111
  13. Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;26(16):2732–2736
  14. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systemic review. Thromb Res. 2009;124(4):409–417
  15. Avram S, Lupu A, Angelescu S, Olteanu N, Mut-Popescu D. Abnormalities of platelet aggregation in chronic myeloproliferative disorders. J Cell Mol Med. 2001;5:79–87
  16. Tsantes A, Mantzios G, Giannopoulou V, Tsirgotis P, Bonovas S, Rapti E, et al. Monitoring aspirin treatment in patients with thrombocytosis: Comparison of the platelet function analyzer (PFA)-100 with optical aggregometry. Thromb Res. 2008;123:100–107
  17. Cesar J, Miguel DD, Garcia A, Burgaleta C. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100. Am J Clin Pathol. 2005;123:772–777
  18. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781–788
  19. Cardinal D, Flower R. The electronic aggregometer: A novel device for assessing platelet behaviour in blood. J Pharmacol Meth. 1980;3:135–158
  20. Angiolillo D, Bernado E, Palazuelos J, Desai B, Weisberg I, Alfonso F, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Thromb Haemost. 2008;99:161–168
  21. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Kastrati A, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:849–856
  22. Velik-Salchner C, Maier S, Innerhofer P, Streif W, Klingler A, Kolbitsch C, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: The results of a pilot study. Anesth Analg. 2008;107:1798–1806
  23. Rahe-Meyer N, Winterhalter M, Boden A, Froemke C, Piepenbrock S, Calatzis A. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand. 2009;53:168–175
  24. Jaffe E, Harris N, Stein H, Vardiman J. World health organization. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, france: IARC Press; 2001;
  25. Robier C, Neubauer M, Sternad H, Brunner E, Stocker H, Quehenberger F, et al. Impact of the platelet count on multiple electrode aggregometry in patients with myeloproliferative disorders and reactive thrombocytosis. Clin Chem Lab Med. 2009;47:47;Special Supplement, p. 227. 18th IFCC – EFCC European Congress of Clinical Chemistry and Laboratory Medicine; 7-11 June 2009; Innsbruck, Austria
  26. Hothorn T, Hornik K, Zeileis A, Wiel Mvd. Implementing a class of permutation tests: The coin package. J Stat Softw. 2008;28:1–23
  27. Manoharan A, Gemmell R, Brighton T, Dunkley S, Lopez K, Kyle P. Thrombosis and bleeding in myeloproliferative disorders: Identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol. 1999;105:618–625
  28. Yamamoto K, Sekiguchi E, Takatani O. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders. Thromb Haemost. 1984;52:292–296
  29. Baker R, Manoharan A. Platelet function in myeloproliferative disorders: Characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol. 1988;40:267–272
  30. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109:2310–2313
  31. Faraday N, Yanek LR, Vaidya D, Kral B, Qayyum R, Herrera-Galeano JE, et al. Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease. Thromb Res. 2009;124:311–317
  32. Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiplate™ whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets. 2007;18(3):199–206
  33. Müller-Schunk S, Linn J, Peters N, Spannagl M, Deisenberg M, Brückmann H, et al. Monitoring of clopidogrel-related platelet inhibition: Correlation of nonresponse with clinical outcome in supraaortic stenting. Am J Neuroradiol. 2008;29(4):786–791
  34. Mueller T, Dieplinger B, Poelz B, Haltmayer M. Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease. Clin Appl Thromb Hemost. 2009;15(6):652–659
  35. Dragani A, Pascale S, Recchiuti A, Mattosclo D, Lattanzlo S, Petrucci G, et al. The contribution of cyclooxygenase-1 and -2 to persistant thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood. 2010;115:1054–1061

PII: S0049-3848(10)00354-3

doi: 10.1016/j.thromres.2010.06.014

Thrombosis Research
Volume 126, Issue 3 , Pages 232-237 , September 2010

Article Tools

* Image Usage & Resolution